Cannabis sativa (Hemp) Seeds, Δ 9 -Tetrahydrocannabinol, and Potential Overdose
Open Access
- 1 January 2017
- journal article
- research article
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 2 (1) , 274-281
Abstract
Introduction: Cannabis sativa (hemp) seeds are popular for their high nutrient content, and strict regulations are in place to limit the amount of potentially harmful phytocannabinoids, especially Δ 9 -tetrahydrocannabinol (Δ 9 -THC). In Canada, this limit is 10 μg of Δ 9 -THC per gram of hemp seeds (10 ppm), and other jurisdictions in the world follow similar guidelines. Materials and Methods: We investigated three different brands of consumer-grade hemp seeds using four different procedures to extract phytocannabinoids, and quantified total Δ 9 -THC and cannabidiol (CBD). Discussion: We discovered that Δ 9 -THC concentrations in these hemp seeds could be as high as 1250% of the legal limit, and the amount of phytocannabinoids depended on the extraction procedure employed, Soxhlet extraction being the most efficient across all three brands of seeds. Δ 9 -THC and CBD exhibited significant variations in their estimated concentrations even from the same brand, reflecting the inhomogeneous nature of seeds and variability due to the extraction method, but almost in all cases, Δ 9 -THC concentrations were higher than the legal limit. These quantities of total Δ 9 -THC may reach as high as 3.8 mg per gram of hemp seeds, if one were consuming a 30-g daily recommended amount of hemp seeds, and is a cause for concern for potential toxicity. It is not clear if these high quantities of Δ 9 -THC are due to contamination of the seeds, or any other reason. Conclusion: Careful consideration of the extraction method is very important for the measurement of cannabinoids in hemp seeds.Keywords
This publication has 18 references indexed in Scilit:
- A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteersSpringerPlus, 2013
- Hippocampal cellular loss after brief hypotensionSpringerPlus, 2013
- Phytocannabinoids as novel therapeutic agents in CNS disordersPharmacology & Therapeutics, 2012
- Phytocannabinoids beyond theCannabisplant – do they exist?British Journal of Pharmacology, 2010
- Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herbTrends in Pharmacological Sciences, 2009
- Polymorphism of human cytochrome P450 enzymes and its clinical impactDrug Metabolism Reviews, 2009
- Human Cannabinoid PharmacokineticsChemistry & Biodiversity, 2007
- Conversion of cannabidiol to Δ9-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in miceForensic Toxicology, 2007
- Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomesLife Sciences, 2007
- GC-MS Analysis of the Total Δ9-THC Content of Both Drug- and Fiber-Type Cannabis SeedsJournal of Analytical Toxicology, 2000